

Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium

Peer-reviewed author version

Blommaert, Adriaan; Bilcke, Joke; VANDENDIJCK, Yannick; Hanquet, Germaine; HENS, Niel & Beutels, Philippe (2014) Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. In: VACCINE, 32 (46), p. 6075-6083.

DOI: 10.1016/j.vaccine.2014.08.085

Handle: <http://hdl.handle.net/1942/17969>

1 **Cost-effectiveness of seasonal influenza vaccination in pregnant women, health** 2 **care workers and persons with underlying illnesses in Belgium**

3 Adriaan Blommaert^{1,2*}, Joke Bilcke¹, Yannick Vandendijck², Germaine Hanquet³, Niel Hens^{1,2} and Philippe
4 Beutels^{1,4}

5 ¹Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine &
6 Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

7 ²Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), Hasselt University,
8 Hasselt, Belgium

9 ³Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium

10 ⁴School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia

11 * Corresponding author. Tel.: +32 3 265 29 37 ; E-mail address: adriaan.blommaert@uantwerp.be;
12 Address: Universiteitsplein 1 R2.12, BE2610 Wilrijk (Antwerpen); Belgium

13

14 **Abstract**

15 Risk groups with increased vulnerability for influenza complications such as pregnant women, persons
16 with underlying illnesses as well as persons who contact them, such as health care workers, are currently
17 given priority (along with other classic target groups) to receive seasonal influenza vaccination in
18 Belgium. We aimed to evaluate the efficiency of this policy by performing cost-effectiveness analysis of
19 increased vaccine uptake in the three specific target groups above, while accounting for effects beyond
20 the target group. Increased influenza vaccine coverage is likely to be cost-effective for pregnant women
21 (median €6,589 per Quality-Adjusted Life-Year (QALY) gained [€4,073-€ 10,249]) and health care workers
22 (median €24,096/QALY gained [16,442-€36,342]), if this can be achieved without incurring additional
23 administration costs. Assuming an additional physician's consult is charged to administer each additional
24 vaccination, the cost-effectiveness of vaccinating pregnant women depends strongly on the extent of its
25 impact on the neonate's health. For health care workers, the assumed number of preventable secondary
26 infections has a strong influence on the cost-effectiveness. Vaccinating people with underlying illnesses
27 is likely highly cost-effective above 50 years of age and borderline cost-effective for younger persons,
28 depending on how this risk group's life expectancy compares to that of the general population. The case-
29 fatality ratios of the target group, of the secondary affected groups and vaccine efficacy are key sources
30 of uncertainty.

31

32 **Keywords**

33 flu; vaccination; risk groups; cost-utility; pregnancy; immuno-compromised; elderly

34 **Introduction**

35 Seasonal influenza causes a substantial number of symptomatic infections, hospitalisations and fatalities,
36 especially in young children, the elderly and people with underlying illnesses [1]. The Superior Health
37 Council of Belgium recommends giving priority to immunizing people at increased risk of influenza
38 complications, namely people living in institutions, people with underlying illnesses and the elderly (>65
39 years). Furthermore, health care workers (HCWs), pregnant women in the 2nd and 3rd trimester of
40 pregnancy, the general population between 50 and 64, and poultry and pig farmers and their household
41 members, have priority over the general population [2]. Prioritization is important, because the demand
42 for influenza vaccines has surpassed supply in recent years [3]. Although these recommendations were
43 based on the medical literature, their potential cost-effectiveness was largely unknown. Also, doubts
44 have been expressed about the usefulness of influenza vaccination in view of uncertainties related to
45 season-specific effectiveness in at-risk groups [4]. Therefore, up to date information on the cost-
46 effectiveness of vaccinating these risk groups, may improve the prioritisation and acceptability of
47 seasonal influenza vaccines. In this paper, we evaluate the cost-effectiveness of increasing seasonal
48 influenza vaccine uptake in (1) pregnant women in their 2nd and 3rd trimester, (2) HCWs and (3) people
49 with underlying illnesses. Currently these groups have relatively low vaccine uptake [3], despite the
50 above recommendations. Cost-effectiveness analyses of influenza vaccination of the elderly are
51 presented elsewhere in combination with childhood vaccination options using a dynamic transmission
52 model [3]. We did not consider here the specific risk group of poultry and pig farmers, because the
53 rationale for their vaccination (recombination of viruses in their work environment with potential risk to
54 the general population) requires a different modelling approach.

55 The cost-effectiveness of vaccinating pregnant women [5-7], HCWs [8-11] and people with underlying
56 illnesses [12-16] has been evaluated before in other countries, but the results depended strongly on
57 assumed vaccine efficacy. In this study, we use the most up to date estimates [17], and consider the
58 potential impact of influenza vaccination beyond the target group. Vaccination during pregnancy has the
59 potential to reduce foetal death through avoided maternal mortality, and confers vaccine-induced
60 immunity to the neonate [18]. In previous cost-effectiveness analyses, these potential effects were not
61 [5, 7] or only partially [6] accounted for. Vaccinating HCWs was also shown to have an effect on the
62 patients they contact [19, 20]. This could be of particular importance for institutionalised or hospitalised
63 patients and the elderly in general, and is therefore also considered in our analyses.

64

65 **Material and methods**

66 *Decision analytic model*

67 Since the groups of pregnant women, HCWs and people with underlying illness are relatively small in
68 Belgium and are not core transmitter groups for the influenza virus, the cost-effectiveness of their
69 vaccination can be analysed using a static model [21]. For each risk group, a decision tree model was
70 developed in the R software. (R development Core Team, 2012, <http://www.R-project.org>). The general
71 structure is displayed in Figure 1 and model parameters are listed in Table 1. The model assumes that
72 susceptible individuals (unvaccinated or vaccinated without being protected) experience an age
73 dependent rate of acquiring a symptomatic influenza infection for which they seek medical care. This
74 rate is based on estimates from a dynamic model for influenza like illness (ILI) fitted to ILI surveillance
75 data [3], combined with laboratory confirmed influenza proportions on these ILI data. We obtained the
76 total number of symptomatic cases and thence the age-specific number of cases who do and do not seek
77 medical care (i.e. do not consult a physician). Thus we obtained the number of cases not receiving
78 medical care, ambulatory cases, hospitalisations and fatalities.

79 Direct medical costs and QALY losses associated with these outcome categories were included in order
80 to compare the costs and QALYs of current with increased vaccine uptake scenarios (up to 50% (40% for
81 persons with underlying illnesses)) [1]. A health care payer perspective was used. Costs and non-fatal
82 health outcomes were not discounted because of the short analytical time horizon (one year). Future
83 life-years lost due to influenza-attributable mortality were discounted at an annual rate of 1.5%, in
84 accordance with Belgian guidelines [22].

85 We assumed the vaccine is offered to pregnant women, on average in calendar week 47 (i.e. mid-
86 November). We assumed also a 4-week delay before vaccinees benefit from vaccine protection. Hence,
87 costs and QALY losses were included for infections occurring between calendar week 51 and 25
88 (assumed end of the influenza season), by using a partial attack rate in the model (84% of the yearly ILI
89 cases occurs in that time window). According to the Belgian guidelines, pregnant women should receive
90 an influenza vaccine during the second or third trimester of their pregnancy, implying the average
91 delivery date of pregnant vaccine recipients is in calendar week 7 (assuming uniformly distributed
92 deliveries over the year and vaccination in calendar week 47). It is assumed that when the pregnant
93 mother dies due to influenza, so does the foetus. Therefore, to account for fatalities in the period leading
94 up to calendar week 7, the discounted expected life years lost of both the mother and her unborn child
95 are summed to calculate the associated cost-effectiveness ratios. From calendar week 7 until week 25,
96 infants can be assumed to be exposed to an autonomous risk of acquiring an influenza infection (one
97 third of the annual attack rate in the infant (<1 year) age category). Within that period we foresee
98 potential transferred vaccine-induced immunity from mother to child. Since the extent to which an
99 immune response may translate into clinical protection is not yet demonstrated for our setting [23], we
100 vary the factor by which vaccine efficacy is transferred from mother to child from 0% over 50% to 100%
101 in sensitivity analysis. We ignore any separate health or cost consequences for the infants due to
102 influenza-related deaths in mothers in the period after birth. Furthermore, we assume identical
103 probabilities for influenza-related hospitalisation and death of the mother before and after giving birth.

104 Finally the occurrence of multiple pregnancies has not been accounted for, since they only make up a
105 small part of the total number of pregnancies.

106 The health outcomes for secondary symptomatic influenza infections amongst patients in contact with
107 health care workers are calculated in the same manner as those for primary infections.

108 *Data sources and input parameters*

109 Table 1 contains all input parameters by risk group. In this subsection, we provide some background and
110 clarification for these parameters.

111 The choice of age groups of people with underlying illnesses and patients in contact with HCWs is based
112 on the available input data and on plausible options for vaccination. Patients in contact with HCWs are
113 conservatively assumed to have the same characteristics (hospitalisation costs, hospitalisation and death
114 rates, etc.) as the general population of the same age class. We limited the analysis to 50 year olds.

115 The number of yearly influenza-related hospitalisations and fatalities were estimated by applying an
116 attributable fraction for influenza to reported influenza and pneumonia hospitalisations and fatalities.
117 This attributable fraction was obtained by regressing weekly counts of influenza and pneumonia
118 admissions and deaths on the weekly numbers of laboratory confirmed cases of respiratory pathogens
119 that may cause influenza-like-illness or pneumonia (influenza (A and B), *S. pneumoniae*, adenovirus,
120 respiratory syncytial virus, *m. pneumoniae*, parainfluenza, and *haemophilus*), population size, holiday
121 and school term indicators. Details of this regression analysis are described elsewhere [3].

122 Cost-effectiveness was only assessed for increased uptake of the trivalent inactivated influenza vaccine
123 (TIV), up to 2013 the only influenza vaccine type available in Belgium, and reimbursed for pregnant
124 women, HCWs and people with underlying illnesses (amongst other risk groups). TIV provides moderate
125 protection against outpatient virologically confirmed influenza with a pooled vaccine efficacy of 59%
126 [95% CI 51%–67%] [17]. This estimate was used irrespective of age or risk class, because there is
127 currently no evidence suggesting differences according to such characteristics [1, 3, 17].

128 *Uncertainty, variable importance and sensitivity analysis*

129 Where appropriate, uncertainty around the input parameters was specified as probability distributions
130 (Table 1, [24]). For the hospitalisation and case-fatality ratios, the number of successes and the number
131 of failures from the beta distribution are based on the predictions obtained from different selected
132 “best” regression models (see above). Model uncertainty was taken into account by randomizing with
133 equal probability between selected regression models for the different outcome measures. To assess the
134 uncertainty of the cost-effectiveness results, we conducted Monte-Carlo sampling with 10,000 draws
135 taken from the joint input distribution, assuming independence of the uncertain input variables (i.e.
136 probabilistic sensitivity analysis).

137 The relative influence of each of the uncertain parameters was investigated by fitting multiple linear
138 regression models with as covariates all standardized uncertain input variables and as response the
139 incremental costs, the incremental QALYs gained and the net benefits. The net benefit was calculated by

140 subtracting the incremental costs from the QALYs gained valued at €35,000 per QALY. In Belgium there is
141 no official willingness to pay threshold to obtain gains in (quality-adjusted) life years, but €35,000 is
142 about the Gross Domestic Product per capita. The amount of GDP per capita has been put forward by
143 the World Health Organization as representing the costs per QALY gained of a 'very cost-effective'
144 strategy [25]. The larger the absolute value of the regression coefficients, the more important the
145 uncertain parameter is in determining the response (incremental costs, QALYs and net benefits).

146 Probabilistic sensitivity analysis was repeated for different key model assumptions regarding clinical
147 protection against influenza transferred from mother to child, the number of influenza cases caused in
148 patients through contacts with health care workers, and life expectancy of people with underlying
149 illnesses relative to that of the general population. An important question regarding implementation is
150 whether we can assume zero marginal administration costs for vaccinating pregnant women or HCWs, or
151 whether an additional GP visit will be charged for these acts. Since this was unknown to the Belgian
152 program managers, both these options were evaluated.

153 Results

154 *Pregnant women*

155 The cost-effectiveness of increasing vaccine uptake in 2nd or 3rd term pregnant women depends on the
156 assumed vaccine administration cost and the degree of vaccine protection indirectly inferred to the new-
157 born child. Increasing vaccine uptake is very likely to be cost-effective when there are no marginal
158 administration costs, or when these remain substantially lower than the current price for a GP
159 consultation. At marginal administration costs of 1 GP consult (€23.32), seasonal influenza vaccination of
160 pregnant women would only be cost-effective, if indirectly transferred vaccine protection to the child is
161 high (i.e. 100% in Figure 2). Figure S1 (in supplementary material) shows the variable importance,
162 indicating that the case-fatality ratio of the mother, vaccine efficacy and QALY loss are all influential.
163 Ignoring the life years lost due to the death of a foetus only has a minor impact on the cost-effectiveness
164 (median ICER of €6,706 instead of €6,616 per QALY gained). With a per-season median of 26 versus 3
165 hospitalisations prevented, the incremental health gains of the program are larger for the neonates than
166 for the pregnant women, respectively (see Table 2). The larger scope for prevented hospitalisations and
167 deaths in neonates is due to the high risks for neonates afflicted by ILI (mean proportion hospitalised
168 2.92%, based on the 0-4 year old age group).

169 *Health care workers*

170 Also for HCWs, vaccine administration costs have a large influence on the cost-effectiveness of influenza
171 vaccination, as well as the extent of indirect protection conferred to patients. That is, the assumed
172 number of secondary symptomatic influenza infections among patients caused by an influenza case in
173 the HCWs is influential. At zero marginal administration costs (i.e. vaccination during a routine medical
174 visit or through occupational health doctor), increased influenza vaccination of active HCWs is likely to
175 be cost-effective, even without accounting for secondary influenza cases (median ICER: €24,103 per
176 QALY gained; 95% ICER range: €16,421-€36,355; see Table S1 in Supplementary material). If we assume

177 at least one secondary symptomatic influenza infection in the elderly patients above 75 years of age per
178 symptomatic infection in the HCWs the program becomes even cost-saving.

179 At marginal administration costs of one GP visit (€23.32), increased influenza vaccine uptake in HCWs
180 can be considered cost-effective, only if at least one secondary symptomatic influenza infection in
181 patients older than 64 is assumed per 3 primary symptomatic infections in the HCWs. Alternatively, at
182 least one secondary influenza case in persons aged 50-64 per primary case in HCWs can compensate for
183 these marginal administration costs (see Figure 3, Table S1 in Supplementary material).

184 Probabilistic sensitivity analysis, assuming one secondary symptomatic influenza infection per
185 symptomatic infection in the target group, reveals that the uncertainties around the case-fatality ratio
186 for secondary cases and the vaccine efficacy exert the highest relative influence on QALYs gained and
187 consequently on the net benefits (see Figure S2 in supplementary material). This finding holds for the
188 different age groups of secondary cases.

189 We additionally investigated splitting up the group of HCWs according to age. Observed changes in ICER
190 values are minor, since differences in input variables between HCW age groups are small.

191 *Persons with underlying illnesses*

192 Increasing vaccine uptake in people with underlying illnesses is cost-effective for persons aged 50 and
193 older, for all life expectancies considered (Figure 4, Table 2). Also for younger persons, it is likely to be
194 cost-effective for most combinations of uncertain parameters and life expectancies. The ICERs become
195 less favourable when life expectancy of younger persons with underlying diseases is assumed to be only
196 30% of that of the general population of the same age group, and for small values of case-fatality ratios.
197 Indeed, the uncertainty around the case-fatality ratio and to a lesser extent around vaccine efficacy are
198 the most influential for all age groups, with the case fatality ratio being more influential in younger age
199 groups. (Figure S3 in Supplementary material)

200 For these youngest age groups (<50 years), we calculated the maximum marginal vaccination costs
201 (vaccine price and administration costs) such that the 95th percentile of the ICER distributions falls below
202 €35,000. For children with underlying illness below 15 years of age, these maximum costs would be
203 €20.44 and €7.57, assuming their life expectancy was 50% and 30%, respectively, of that of an average
204 child below 15 years of age. For the age group 15-49, such a maximum amount cannot be found using
205 the same assumptions for life expectancy (i.e. at zero marginal costs the 95th percentile is above
206 €35,000).

207 Discussion

208

209 For pregnant women, we found increased influenza vaccine uptake to be particularly cost-effective
210 (median ICER < €10,000 per QALY gained). This result is similar to that of Jit et al. [6], when assuming
211 identical administration costs. Jit et al did not attribute life years lost to fetal death, but used a higher
212 overall vaccine efficacy estimate.

213 Also for elderly with underlying illness (65+), increased vaccine uptake yielded generally acceptable cost-
214 effectiveness. This contrasts with the few other studies for this target group (summarized in de Waere et
215 al. [26]), mainly because we used a more favorable rapport between vaccine efficacy and occurrence of
216 preventable disease. Cost-effectiveness fundamentally depends on relating vaccine efficacy on
217 appropriate outcomes to reliable estimates of the occurrence of such outcomes in the context of the
218 envisaged target group, for which we used the most specific, soundest and latest evidence [17, 27].

219 Ours is one of the few studies to evaluate the cost-effectiveness of influenza vaccination in HCWs [27].
220 We demonstrated that the cost-effectiveness of vaccinating HCWs depends strongly on the assumed
221 number of secondary symptomatic influenza infections prevented in patients they contact, as well as
222 these patients' ages and vulnerability to influenza. Up to now only Chicaiza-Becerra et al. [11] included
223 such patient benefits. They found vaccination of Colombian HCWs who care for cancer patients, to be
224 cost saving. Some of the studies not accounting for patient benefits, also reported favourable results [8,
225 10, 28]. Furthermore, there is empirical evidence to show that vaccination of HCWs might be more
226 effective in preventing disease and death in the elderly in long-term care, than vaccinating these elderly
227 patients directly [19, 20]. These results are likely to be generalizable to HCWs making contact with other
228 vulnerable groups such as people living in institutions and persons with severe underlying illnesses.

229 Our findings are based on the currently available evidence on vaccine efficacy and disease burden in the
230 specific risk groups, combined with plausible assumptions inferred from the literature. For instance,
231 vaccine efficacy was assumed constant over the different age and risk groups considered here since the
232 most recent authoritative trial review found no age difference (in <65 years of age, [17]) and more
233 recent observational studies found similar efficacy across risk groups [29-32]. Clearly, if future research
234 would show vaccine efficacy to be lower in elderly with underlying illnesses, the cost-effectiveness of
235 their vaccination would become less attractive. Better knowledge of vaccine efficacy would strongly
236 reduce uncertainty in all presented cost-effectiveness results, because it remains a main source of
237 uncertainty (see large impact of vaccine efficacy on the net benefit in Figure S1 in supplementary
238 material), together with the case-fatality and hospitalisation ratios.

239 The basic structure of our decision-analytic model is rather conservative. Firstly, for pregnant women
240 and people with underlying illnesses, herd immunity was not accounted for. Indeed, for these target
241 groups herd immunity is likely to be negligible, because they are not core transmitter groups in the
242 general population or in specific settings. Secondly, we assumed the vaccine would only protect for one
243 season against the circulating strains. However, it seems plausible that some vaccine recipients would
244 enjoy some residual protection into the next season, and that therefore this is also a conservative

245 assumption. Thirdly, we opted for a mean approach for the relative timings of vaccination of pregnant
246 women in relation to the onset of the influenza season and gestational age, based on previous seasons.
247 However, previous studies found assumptions regarding these relative timings to be influential for the
248 cost-effectiveness [6, 7]. Clearly, vaccination of second or third term pregnant women is more effective
249 and cost-effective, if it can take place before or as early as possible in the flu season.

250 **Acknowledgments**

251 This study was commissioned and co-financed by the Health Care Knowledge Centre (KCE) of the Belgian
252 Federal government. Adriaan Blommaert acknowledges support from the University of Antwerp
253 concerted research action number 23405 (BOF-GOA); Joke Bilcke is supported by a postdoctoral grant
254 from the Science Foundation Flanders (FWO); Yannick Vandendijck is supported by a doctoral grant of
255 Hasselt University (BOF11D04FAEC). We also gratefully acknowledge financial support by the IAP
256 Research Network P7/06 of the Belgian State (Belgian Science Policy).

257 We are grateful to dr. Benson Ogunjimi for reviewing diagnostic codes on underlying illnesses, to Nancy
258 Thiry for performing the literature review on quality of life estimates, to France Vrijens and Carl Devos
259 for support in the regression analysis and to the Scientific Institute of Public Health (ISP – WIV), the UZ
260 Leuven Reference Laboratory for *Streptococcus pneumoniae*, the Technical Cell for the Minimal Clinical
261 Data, the Wallonia-Brussels Federation, the Flemish Agency for Care and Health and the Brussels-Capital
262 Health and Social Observatory for providing data for the regression analysis on admissions and deaths.
263 This study benefited from discussions held within the context of KCE report 204, the expert committee of
264 which included: Rik Baeten (VIGEZ), Johan Bots (Gemeenschappelijke Gemeenschapscommissie),
265 Liesbeth Dejaegere (VIGEZ), Ann Malfroot (UZ Brussel), Daniel Reynders (SPF Santé Publique – FOD
266 Volksgezondheid), Béatrice Swennen (Université Libre de Bruxelles), Isabelle Thomas (ISP – WIV), Geert
267 Top (Vlaams Agentschap Zorg en Gezondheid), Patrick Tréfois (Question Santé), Yves Van Laethem
268 (Centre Hospitalier Universitaire St. Pierre), Anne Vergison (Université Libre de Bruxelles), Françoise
269 Willaume (ISP – WIV).
270

271 **Author contributions**

272 PB conceived the study. AB developed and implemented the model. GH, YV, JB and PB provided input
273 data. AB performed and interpreted the analyses, with revisions by PB, JB and GH. AB, PB and JB wrote
274 the manuscript, which GH, JV and NH critically revised. All authors approved the final version of the
275 manuscript

276 **Conflicts of interest**

277 The authors have no conflicts of interest to declare.

278

	Value or distribution			
Parameter	Pregnant women ^a	Health Care Workers ^a	People with underlying illnesses	Source
<i>Vaccination program and vaccine characteristics</i>				
Size target group	121,363	239,740	117,473 (0-14 years of age) 407,613 (15-49 years of age) 320,672 (50-64 years of age) 559,788 (over 65 years of age)	[1]
Vaccine uptake (P_{vac})	0.50 increased uptake scenario 0 current uptake scenario (assumed)	0.50 increased uptake scenario 0.35 current uptake scenario	0.40 increased uptake scenario 0.20 current uptake scenario	[1]
Fixed marginal cost vaccination programme	€ 0			
Variable vaccination costs: TIV per dose	€ 11.81			[33]
Variable administration cost per dose (GP visit in Belgium)	€ 0 or € 23.32	€ 0 or € 23.32	€ 23.32	[33]
Vaccine efficacy of the TIV vaccine (ϵ)	Gaussian(mean=0.59; sd=0.04)			[17]
<i>Epidemiological parameters</i>				
Yearly attack rate of influenza like illness (ILI) seeking medical care (λ_{ILI})	Weighted average over the age distribution			The yearly attack rate for patients with ILI seeking medical care was obtained by dividing the predicted number of ILI infections, under current vaccination coverage, from a dynamic transmission model [3] by the population size in that age cohort.
The proportion of influenza within the ILI cases seeking medical care (P_{influ})	<ul style="list-style-type: none"> Beta(2,070; 2,075) for pregnant women Beta(132; 2,075) for neonates 	Beta(2,070; 2,075)	<ul style="list-style-type: none"> Beta(751; 593) (0-14 years of age) Beta(2,070; 2,075) (15-49 years of age) 	[3]

			<ul style="list-style-type: none"> Beta(2,070; 2,075) (50-64 years of age) Beta(142; 202) (over 65 years of age) 	
The proportion of symptomatic influenza cases who do not seek medical care: no GP visit, not hospitalised. ($P_{\text{no med}}$)	Beta(1,107; 1,143)			[3]
The hospitalisation rate of influenza cases seeking medical care (τ)	<p>We randomize with equal probability between 3 scenarios:</p> <ul style="list-style-type: none"> Beta(7, DENOM^b-7) Beta(11, DENOM^b-11) Beta(15, DENOM^b-15) 	<p>We randomize with equal probability between 2 scenarios:</p> <ul style="list-style-type: none"> Beta(18, DENOM^b-18) Beta(55, DENOM^b-1.3) 	<ul style="list-style-type: none"> Beta(76, DENOM^b-76) (0-14 years of age) Beta(127, DENOM^b-127) (15-49 years of age) Beta(160, DENOM^b-160) (50-64 years of age) <p>For the age group over 65 years, we randomize with equal probability from the hospitalisation rates of the general population of that age (see reference)</p>	[3]
The case fatality ratio of influenza cases seeking medical care (μ)	<p>For pregnant women we randomize between 2 scenarios</p> <p>Beta(0.1, DENOM^c-0.1) Beta(0.2, DENOM^c-0.2)</p> <p>For neonates we randomize between model predictions of the general (hospitalised) population between 0-5 years of age^d</p>	<p>For HCW, we randomize between 2 scenarios:</p> <ul style="list-style-type: none"> Beta(0.6, DENOM^b-0.6) Beta(1.3, DENOM^b-1.3) <p>We randomize between models for the elderly (hospitalised) population^c</p>	<ul style="list-style-type: none"> Beta(2, DENOM^b-2) (0-14 years of age) Beta(8, DENOM^b-8) (15-49 years of age) Beta(30, DENOM^b-30) (50-64 years of age) <p>For the age group over 65 years we randomize from the case fatality ratios of the general (hospitalised) population of that age^c</p>	[3]
Outcomes: quality of life and life expectancy				
QALY loss for an ambulatory patient	0.0071 (sampling from 8 Gaussian distributions: 7 days for which VAS scores were measured + number of days with symptoms)			[34], [3]

Duration of symptoms for an ambulatory patient	Gaussian (mean=6.43; sd=0.14)			[3]
Duration of symptoms for a hospitalised patient	Gaussian (mean=8.5; sd=1.04)			[3]
Duration of symptoms for a person not seeking medical care	Gaussian (mean=5.51; sd=0.14)			[3]
QALY loss for a hospitalised patient	QALY loss ambulatory patient * ratio duration of symptoms hospitalised patient and duration of symptoms ambulatory patient			Assuming average QALY loss for a day with influenza does not differ between ambulatory patients, hospitalised patients and persons not seeking medical care [34], [3]
QALY loss for a person not seeking medical care	QALY loss ambulatory patient * ratio duration symptoms person not seeking medical care and duration of symptoms ambulatory patient			
Life expectancy	as a function of age	as a function of age	as a function of age multiplied with a factor 1 or 0.5 or 0.3 to investigate the influence of shorter life expectancy due to underlying illnesses	[3]
Outcomes: Costs: We use a single randomization parameter for the following 3 cost categories, to randomize between the highest and lowest costs with equal probability				
Out-of-hospital costs for a hospitalised patient	lowest unit costs: Gaussian(mean=€119.65, sd=€17.69)			[3]
	highest unit costs: Gaussian(mean=€139.94, sd=€20.19)			[3]
Cost for an ambulatory patient (i.e. consulting GP) (no difference between ILI and influenza)	lowest unit costs: Gaussian(mean=€51.04, sd=€1.18)			[3]
	highest unit costs: Gaussian(mean=€63.8, sd=€1.34)			[3]
Cost for a person with ILI not seeking medical care	lowest unit costs: Gaussian (mean=€3.39, sd=€0.21)			[3]

	highest unit costs: Gaussian (mean=€7.17, sd=€0.37)			[3]
In-hospital cost for a hospitalised patient ^d	<p>For pregnant women, we randomize between two options:</p> <ul style="list-style-type: none"> • weighted average of primary influenza hospitalisation costs, for women with primary diagnosis influenza (€ 1838.16) and • cost of women with primary diagnosis influenza and secondary diagnosis pregnancy complication (€ 1,481); <p>For neonates we use the average hospitalisation cost of primary diagnosis influenza (€ 2,572)</p>	<p>Depending on the age group:</p> <ul style="list-style-type: none"> • €2,513 (HCW, 20-65 years of age) • €1,653 (HCW, 20-29 years of age) • €2,300 (HCW, 30-49 years of age) • €3,660 (HCW, 50-65 years of age) • €3,660 (elderly, 50-64 years of age) • €4,825 (elderly 65-74 years of age) • €5,664 (elderly, over 75 years of age) 	<p>We calculate the cost per age of admission^b:</p> <ul style="list-style-type: none"> • €3,437 (0-14 years of age) • €4,576 (15-49 years of age) • €6,293 (50-64 years of age) • €7,507 (65+ years of age) 	[3]
Discount rates				
Discount rate for costs	0.03			[22]
Discount rate for health effects	0.015			[22]
Specific factors for the pregnancy model				
Proportion of attack rate ($\lambda_{i,l}$) exposure during pregnancy and during the period of vaccine protection for the	0.84	-	-	See attack rate ($\lambda_{i,l}$)

cohort giving birth, on average, on 15th February. This period is defined as week 51-week 25				
In mothers who acquire influenza and die during pregnancy, the proportion of neonates who are not yet born. (Cases week 51-week 7 of the mother/ cases week 51-25 for women)	0.58	-	-	See attack rate (λ_{ILI})
Proportion of the attack rate (λ_{ILI}) applicable to neonates after they are born. (week 8-25)	0.33	-	-	See attack rate (λ_{ILI})

281 ^a Pregnant women's age based on range 15 to 49 years (youngest and oldest mother in Belgium 2011), the health care workers' age is based on the entire age range of HCWs in
282 Belgium (20-65 years), but narrower age categories (20-30; 30-50 and 50-65 years of age) are used in sensitivity analyses.

283 ^b DENOM refers to the denominator of the case fatality ratio and hospital rate, and has the meaning of the number of Influenza cases seeking medical care sampled from a run of
284 the static model (see Figure 1) with the current uptake scenario vaccination coverage. Working with model based versus observed denominators had an ignorable impact on the
285 cost-effectiveness.

286 ^b Hospitalisation rates and case fatality ratios of an age class of the general population were calculated by applying the attributable fraction of influenza derived from regression
287 models to the observed number of influenza and pneumonia per observed influenza cases in the target group.

288 ^d People with underlying illnesses were identified by looking for following underlying ICD-9 diagnostic codes (<http://icd9.chrisendres.com>): asthma (493; V17.5), cardiovascular
289 disease (989.1, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428, 413, 412, 410, 411, 414, 420, 422), chronic obstructive pulmonary disorder (490-
290 492), diabetes (249, 250, V18.0, V77.1, 253.5, 588.1), HIV (042), hypertension (401-405, 997.91, 459.3) and stroke (430-438, 342).

291 ^e Direct costs for a deceased person are implicitly accounted for in the costs for medication, GP visit and hospitalisation, as the sum of these 3 relates to the total number of
292 influenza cases (including those who die from influenza)

293 TIV: Trivalent Inactivated Influenza Vaccine; HCW: health care workers; CFR: case-fatality ratio; ILI: Influenza like illness

294 Age specific parameters such as the attack rate, hospitalisation costs and life expectancy were summarized by taking averages, weighted by the age distribution in the general
295 population in 2011. For pregnant women, the weights were based on the frequency of live births by age of the mother.

296

297 **Table 2: Incremental direct costs, Quality-Adjusted Life-years (QALYs) and cost-effectiveness ratio (ICER) of increased seasonal influenza vaccination uptake**
 298 **in different target groups. Results of 10,000 simulations, presented as median (mean) [95% range] (price level 2011)**

	Pregnant women ^a (121,363 persons)	Health care workers ^b (239,740 persons)	People with underlying illnesses ^c			
			0-14 years of age (117,473 persons)	15-49 years of age (407,613 persons)	50-64 years of age (320,672 persons)	Over 65 years of age (559,788 persons)
Program coverage	From 0% to 50%	From 35% to 50%	From 20% to 40%	From 20% to 40%	From 20% to 40%	From 20% to 40%
Assumed marginal administration costs	€0	€0	€23.32	€23.32	€23.32	€23.32
hospitalisations prevented - neonate	26 (26) [20-33]	-	-	-	-	-
hospitalisations prevented – target group	3 (3) [1-5]	3 (4) [1-8]	10 (10) [8-13]	17 (17) [13-21]	21 (21) [17-26]	156 (166) [99-249]
Deaths prevented - neonate	0.07 (0.09) [0.04- 0.33]	-	-	-	-	-
Deaths prevented – target group	0.00 (0.04) [0.00- 0.33]	0.07 (0.10) [0.00- 0.42]	0.23 (0.27) [0.03- 0.77]	1.02 (1.06) [0.45-1.93]	3.96 (4.02) [2.63-5.77]	42.41 (43.53) [31.10- 58.71]
Incremental direct costs	€385,978 (€383,962) [€309,787- €450,365]	€709,703 (€709,133) [€673,983- €740,952]	€689,687 (€689,189) [€658,694- €716,877]	€2,476,027 (€2,473,748) [€2,388,545- €2,552,104]	€1,902,263 (€1,901,102) [€1,830,151- €1,967,352]	€2,587,383 (€2,513,987) [€1,857,678-€3,044,346]
Incremental QALYs	58 (59) [40-85]	29 (30) [20-43]	31 (33) [20-56]	100 (101) [70-139]	132 (133) [97-176]	518 (529) [382-708]
ICER	€6,616 (€6,763) [€4,097-€10,345]	€24,096 (€24,595) [€16,442-€36,342]	€22,008 (€22,596) [€12,180-€36,574]	€24,768 (€25,278) [€17,623-€35,725]	€14,378 (€14,610) [€10,627-€20,005]	€4,784 (€4,932) [€2,797- €7,607]


299 ^a Assuming 100% vaccine efficacy transfer, leading to clinical protection, from mother to child through maternal antibodies

300 ^b Assuming no secondary influenza infections in the patients they contact

301 ^c Assuming the same life expectancy as the general population of the same age

302

303 **Figure 1: Basic structure of the static model**




304

305 Full arrows indicate the causal structure of the model. Dashed arrows indicate how the group sizes were calculated, when it is different from the causal
 306 structure, and how the sizes of the different groups were calculated using the input data available in Table 1. $F_1 = \lambda_{ILI} * P_{influ}$; $F_2 = F_1 * (1 - \epsilon)$; $F_3 = 1 / (1 - P_{nomed})$; $F_4 =$
 307 $1 - \mu - \tau$; P_{vac} is the vaccination coverage of the target group; λ_{ILI} is the yearly attack rate of influenza like illness (ILI) for which medical care is sought; P_{influ} is the
 308 proportion of influenza relative to the ILI cases seeking medical care; ϵ is the vaccine efficacy against influenza; τ is the influenza hospitalisation rate, μ the
 309 influenza death rate and P_{nomed} is the proportion of symptomatic influenza cases not seeking medical care (see also Table 1).

310


311 Figure 2: Cost-effectiveness acceptability curves for vaccinating 50% versus 0% of 2nd or 3rd term pregnant women while varying the administration cost from
312 €0 to €23.32 and the percentage of transferred vaccine efficacy from mother to child after birth from 0% over 50% to 100%. The vertical bar indicates a
313 willingness to pay for a Quality-Adjusted Life-Year (QALY) of €35,000.

314




315

316 Figure 3: Cost-effectiveness acceptability curves for vaccinating 50% versus 35% of health care workers 20-65 years of age, with varying numbers of
 317 secondary infections in elderly patient groups of various ages ("sec. inf. eld." In graph legend), assuming marginal administration costs of €23.32. The
 318 vertical bar indicates a willingness to pay for a Quality-Adjusted Life-Year (QALY) of €35,000.



320 Figure 4: Cost-effectiveness acceptability curves for vaccinating 40% versus 20% of people with underlying illnesses, while varying their life expectancy (LE)
 321 from 100% over 50% to 30% of that of the general population of the same age. The vertical bar indicates a willingness to pay for a Quality-Adjusted Life-Year
 322 (QALY) of €35,000.



323

324

325 **References**

- 326 [1] Hanquet G, Jonckheer P, Vlayen J, Vrijens F, Thiry N, Beutels P. Seasonal influenza vaccination:
327 priority target groups - Part 1. Good Clinical Practice (GCP). Brussels: Belgian Health Care Knowledge
328 Centre (KCE). 2011;KCE Reports 162C. D/2011/10.273/45.
- 329 [2] Belgian Health Council. Vaccination contre la grippe saisonnière Saison hivernale 2010 - 2011.
330 Brussels: Belgian Health Council. 2010;September 2010. 8682.
- 331 [3] Beutels P, Vandendijck Y, Willem L, Goeyvaerts N, Blommaert A, Van Kerckhove K, et al. Seasonal
332 influenza vaccination: prioritizing children or other target groups? Part II: cost-effectiveness analysis.
333 Brussels: Belgian Health Care Knowledge Centre (KCE). 2013;KCE Reports 204S2. D/2013/10.273/47.
- 334 [4] Jefferson T. Influenza vaccination: policy versus evidence. *BMJ*. 2006;333:912-5.
- 335 [5] Beigi RH, Wiringa AE, Bailey RR, Assi T-M, Lee BY. Economic Value of Seasonal and Pandemic Influenza
336 Vaccination during Pregnancy. *Clinical Infectious Diseases*. 2009;49:1784-92.
- 337 [6] Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E. The cost-effectiveness of vaccinating
338 pregnant women against seasonal influenza in England and Wales. *Vaccine*. 2010;29:115-22.
- 339 [7] Myers ER, Misurski DA, Swamy GK. Influence of timing of seasonal influenza vaccination on
340 effectiveness and cost-effectiveness in pregnancy. *American Journal of Obstetrics and Gynecology*.
341 2011;204:S128-S40.
- 342 [8] Festini F, Biermann KP, Neri S, Reali MF, de Martino M. Influenza vaccination of nurses in an Italian
343 pediatric hospital: effects on absenteeism and on costs, factors associated with vaccine uptake and
344 analysis of personal motivations. *Assist Inferm Ric*. 2007;26:5-13.
- 345 [9] Dutheil F, Delaire P, Boudet G, Rouffiac K, Djeriri K, Souweine B, et al. [Cost/effectiveness comparison
346 of the vaccine campaign and reduction of sick leave, after vaccination against influenza among the
347 Clermont-Ferrand University Hospital staff]. *Medecine et maladies infectieuses*. 2008;38:567-73.
- 348 [10] Colombo GL, Ferro A, Vinci M, Zordan M, Serra G. Cost-benefit analysis of influenza vaccination in a
349 public healthcare unit. *Therapeutics and clinical risk management*. 2006;2:219-26.
- 350 [11] Chicaiza-Becerra LA, Garcia-Molina M, Ballesteros M, Gamboa O, Diaz J, Vega R. Economic
351 evaluation of influenza vaccine applied to health personnel attending hospitalised oncological patients.
352 *Rev Salud Publica (Bogota)*. 2008;10:756-66.
- 353 [12] Abbott KC, Yuan CM, Lee JL. Nothing to sneeze at: efficacy and cost-effectiveness of the influenza
354 vaccine in patients receiving long-term dialysis. *American Journal of Kidney Diseases*. 2011;57:651-3.
- 355 [13] Lee BY, Stalter RM, Bacon KM, Tai JH, Bailey RR, Zimmer SM, et al. Cost-effectiveness of adjuvanted
356 versus nonadjuvanted influenza vaccine in adult hemodialysis patients. *American Journal of Kidney
357 Diseases*. 2011;57:724-32.
- 358 [14] Nosyk B, Sharif B, Sun H, Cooper C, Anis AH. The Cost-Effectiveness and Value of Information of
359 Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus. *Plos
360 One*. 2011;6:e27059.
- 361 [15] Teufel RJ, Basco WT, Simpson KN. Cost effectiveness of an inpatient influenza immunization
362 assessment and delivery program for children with asthma. *J Hosp Med*. 2008;3:134-41.
- 363 [16] Trogdon JG, Nurmagambetov TA, Thompson HF. The Economic Implications of Influenza Vaccination
364 for Adults with Asthma. *Am J Prev Med*. 2010;39:403-10.
- 365 [17] Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a
366 systematic review and meta-analysis (vol 12, pg 36, 2012). *Lancet Infect Dis*. 2012;12:655-.
- 367 [18] Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza
368 immunization in mothers and infants. *The New England journal of medicine*. 2008;359:1555-64.

- 369 [19] Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. Effects of influenza
370 vaccination of health-care workers on mortality of elderly people in long-term care: a randomised
371 controlled trial. *Lancet*. 2000;355:93-7.
- 372 [20] Potter J, Stott DJ, Roberts MA, Elder AG, Odonnell B, Knight PV, et al. Influenza vaccination of health
373 care workers in long-term-care hospitals reduces the mortality of elderly patients. *Journal of Infectious*
374 *Diseases*. 1997;175:1-6.
- 375 [21] Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, et al. Economic evaluation of
376 vaccination programmes: a consensus statement focusing on viral hepatitis. *PharmacoEconomics*.
377 2002;20:1-7.
- 378 [22] Cleemput I, Neyt M, Van De Sande S, Thiry N. Belgian guidelines for economic evaluations and
379 budget impact analyses: second edition. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg
380 (KCE) . KCE Reports 183C. 2012.
- 381 [23] Skowronski DM, De Serres G. Is routine influenza immunization warranted in early pregnancy?
382 *Vaccine*. 2009;27:4754-70.
- 383 [24] Briggs A, Sculpher M, Claxton K. *Decision Modelling for Health Economic Evaluation*. Oxford: Oxford
384 University Press; 2006.
- 385 [25] World Health Organization (WHO). Threshold values for intervention cost-effectiveness by Region.
386 http://www.who.int/choice/costs/CER_levels/en/index.html2012.
- 387 [26] de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, et al. Economic value of
388 influenza vaccination. *Hum Vaccin Immunother*. 2012;8:119-29.
- 389 [27] Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal
390 influenza vaccination strategies. *Human vaccines & immunotherapeutics*. 2013;9:834-40.
- 391 [28] Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E, et al. Vaccinating healthcare workers
392 against influenza to protect the vulnerable - Is it a good use of healthcare resources? A systematic review
393 of the evidence and an economic evaluation. *Vaccine*. 2006;24:4212-21.
- 394 [29] Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, et al. Effectiveness of
395 Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine
396 Strains. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*.
397 2012.
- 398 [30] Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the
399 elderly: is it real, or is it relevant? *Journal of Infectious Diseases*. 2008;197:490-502.
- 400 [31] Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, et al. Estimates of
401 influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-
402 protection against major and minor variants. *Journal of Infectious Diseases*. 2012;205:1858-68.
- 403 [32] Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, et al. Safety and immunogenicity of
404 trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
405 *Pediatric Infectious Disease Journal*. 2010;29:105-10.
- 406 [33] Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd
407 Geneesmiddelenrepertorium. <http://www.bcfi.be/ggr/index.cfm?ggrWelk=MAIN2012>.
- 408 [34] O'Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M. Oseltamivir for treatment of influenza in
409 healthy adults: pooled trial evidence and cost-effectiveness model for Canada. *Value Health*. 2003;6:116-
410 25.

411

412